XCSport体育
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
XCSport体育:Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
XCSport体育:Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
XCSport体育:Manufacturing
XCSport体育:Collaborations
Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
Stock Info
XCSport体育:IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
XCSport体育:Press Release
XCSport体育:Multi-media
Media Reports
Media Enquiry
Careers
Talent Philosophy
XCSport体育:Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
XCSport体育:Customer Message
Privacy
XCSport体育:Legal Statement
XCSport体育:Compliance
EN
简体
EN
繁體
Home
XCSport体育:About Henlius
Company Profile
XCSport体育:Corporate Culture
Honor
XCSport体育:Board of Directors
Management Team
Advisory Committee
Product
XCSport体育:Marketed Products
XCSport体育:Products in R&D
XCSport体育:Clinical Trial
XCSport体育:Science & Technology
R&D Result
Innovation Centre
Technology Platform
XCSport体育:Quality Management
Manufacturing
Collaborations
XCSport体育:Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
Talent Philosophy
XCSport体育:Staff Life
Training and Development
Job Opportunities
Contact Us
XCSport体育:Contact Information
XCSport体育:Customer Message
Privacy
XCSport体育:Legal Statement
Compliance
搜索
Be the most trusted biotech company
XCSport体育:Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
XCSport体育:Multi-media
Company
Popular Science
Highlights
Download
XCSport体育:Media Reports
XCSport体育:Media Enquiry
2025-12-24
First Chinese Patient Dosed for Phase 3 MRCT on ER+/HER2- Breast Cancer of HLX78
2025-12-20
Latest Results of Serplulimab in The Field of Pancreatic Cancer Released In APA/JPS/CAP/IAP 2024 Annual Meeting in Oral Presentation
2025-12-19
Palleon Pharmaceuticals and Henlius Collaborate to Advance Glycan Editing as a Treatment for Autoimmune Diseases
2025-12-17
Henlius Becomes Newest Member of Biosimilars Forum
2025-12-16
Latest Results of Serplulimab in The Neoadjuvant Treatment of ESCC Released In 2024 ESMO IO
2025-12-09
Latest Results of 5 Clinical Trials Released at ESMO Asia 2024
2025-12-04
Henlius Receives IND Approval from NMPA for a Phase 1b/2 Clinical Trial of Its Novel PD-L1-Targeting ADC HLX43
2025-12-04
Henlius Receives Approval form NMPA for a Phase 2 Clinical Trial of Its Novel Anti-HER2 mAb HLX22
2025-12-04
China NMPA Accepts Henlius' NDA for HLX11, an Pertuzumab Biosimilar Candidate
1
2
3
...
10